All Stories

  1. Oral antineoplastic agents: assessment of safety and dose adjustments in clinical practice

    Article • Expert Opinion on Drug Safety, July 2019, Taylor & Francis

    José Luis Revuelta

  2. The concurrent use of OBV/PTV/r+DSV with sorafenib was considered safe and effective in our study.

    Article • Journal of Clinical Pharmacy and Therapeutics, June 2018, Wiley

    José Luis Revuelta

  3. Rilpivirine and dolutegravir in treatment-experienced HIV patients

    Article • Annals of Pharmacotherapy, August 2017, SAGE Publications

    José Luis Revuelta